Canaccord raised the firm’s price target on AtriCure (ATRC) to $53 from $49 and keeps a Buy rating on the shares. The firm said they beat Q3 estimates and management raised Q4 guidance. The solid quarter was driven broadly across the businesses, aside from minimally invasive ablation/EPi-Sense, which continues to face expected headwinds from PFA adoption. Management remains steadfast that these headwinds will subside, pointing towards its experience in Europe.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC: